Literature DB >> 8445737

Sequence specificity of the core-binding factor.

I N Melnikova1, B E Crute, S Wang, N A Speck.   

Abstract

The core-binding factor (CBF) binds the conserved core motif in mammalian type C retrovirus enhancers. We analyzed the phosphate contacts made by CBF on the Moloney murine leukemia virus enhancer by ethylation interference assay. The phosphate contacts span 9 bp centered around the consensus core site. To examine the sequence preferences for CBF binding, we employed the technique of selected and amplified binding sequence footprinting (T. K. Blackwell and H. Weintraub, Science 250:1104-1110, 1990). The consensus binding site for CBF defined by selected and amplified binding sequence footprinting is PyGPyG GTPy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445737      PMCID: PMC240414     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer.

Authors:  Y Kamachi; E Ogawa; M Asano; S Ishida; Y Murakami; M Satake; Y Ito; K Shigesada
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design.

Authors:  E A Golemis; N A Speck; N Hopkins
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer.

Authors:  N A Speck; D Baltimore
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

4.  Differential protein binding in lymphocytes to a sequence in the enhancer of the mouse retrovirus SL3-3.

Authors:  A Thornell; B Hallberg; T Grundström
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

5.  Elution of proteins from sodium dodecyl sulfate-polyacrylamide gels, removal of sodium dodecyl sulfate, and renaturation of enzymatic activity: results with sigma subunit of Escherichia coli RNA polymerase, wheat germ DNA topoisomerase, and other enzymes.

Authors:  D A Hager; R R Burgess
Journal:  Anal Biochem       Date:  1980-11-15       Impact factor: 3.365

6.  Nucleotide sequences of the murine retrovirus Friend SFFVp long terminal repeats: identification of a structure with extensive dyad symmetry 5' to the TATA box.

Authors:  S P Clark; T W Mak
Journal:  Nucleic Acids Res       Date:  1982-05-25       Impact factor: 16.971

7.  Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.

Authors:  A L Boral; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

8.  Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity.

Authors:  N A Speck; B Renjifo; E Golemis; T N Fredrickson; J W Hartley; N Hopkins
Journal:  Genes Dev       Date:  1990-02       Impact factor: 11.361

9.  Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers.

Authors:  S W Wang; N A Speck
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  49 in total

1.  Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.

Authors:  M J Martiney; K Rulli; R Beaty; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 2.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

3.  A bacterial one-hybrid system for determining the DNA-binding specificity of transcription factors.

Authors:  Xiangdong Meng; Michael H Brodsky; Scot A Wolfe
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

4.  The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.

Authors:  S W Hiebert; W Sun; J N Davis; T Golub; S Shurtleff; A Buijs; J R Downing; G Grosveld; M F Roussell; D G Gilliland; N Lenny; S Meyers
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

5.  ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.

Authors:  Jennifer A Mertz; Ryuji Kobayashi; Jaquelin P Dudley
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

6.  AML1 is expressed in skeletal muscle and is regulated by innervation.

Authors:  X Zhu; J E Yeadon; S J Burden
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Developmental cis-regulatory analysis of the cyclin D gene in the sea urchin Strongylocentrotus purpuratus.

Authors:  Christopher M McCarty; James A Coffman
Journal:  Biochem Biophys Res Commun       Date:  2013-10-01       Impact factor: 3.575

8.  Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.

Authors:  A L Zaiman; A F Lewis; B E Crute; N A Speck; J Lenz
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.

Authors:  S Wang; Q Wang; B E Crute; I N Melnikova; S R Keller; N A Speck
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

Review 10.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.